Introduction {#s1}
============

Asthma is known to display different phenotypes across the life-course, suggesting that age related changes are particularly relevant to understanding asthma pathogenesis and remission ([@B1]). We previously demonstrated that bronchodilator response (BDR), which is associated with asthma, is reduced with age, at rate of 0.24 percent per year ([@B2]). The biological mediators of this age-related change are not yet understood. The metabolome may be a key source of intermediary biomarkers that contribute to clinical phenotypes in asthma, especially given that metabolites directly reflect alterations in host biochemical pathways. In fact, metabolite profiles have been associated with lung function outcomes in children with asthma ([@B3]). In this study, our objective was to interrogate the serum metabolome to determine whether circulating metabolites mediate age-related changes in BDR in children and young adults with asthma.

Methods {#s2}
=======

To estimate the effects of metabolite mediators, we used data from the Childhood Asthma Management Program (CAMP), a multi-center, randomized, double-masked, clinical trial designed to determine the long-term effects of treatment with budesonide, nedocromil, or a placebo for mild to moderate asthma in children ([@B4]). A total of 1,041 children, 5--12 years of age, were enrolled in the trial between December 1993 and September 1995. Inclusion was restricted to children with a history of chronic asthma who, during a 28-day run-in period, had asthma symptoms or a low morning peak flow on 8 or more days; inclusion also required a methacholine challenge with a concentration of 12.5 mg per milliliter or less that resulted in a reduction in FEV~1~ by at least 20% \[since airway responsiveness is determined by the provocative concentration of methacholine required to reduce the FEV1 by at least 20% (methacholine PC20), with higher values indicating less airway responsiveness\]. Participants attended 3 clinical trial "visits" per year and treatment was continued for a mean of 4.5 years. Following the end of the treatment component of the trial in 1999, asthma care was transferred to each participants\' health care provider. Over 85% of the original 1,041 participants participated in the 4 month transition phase (2 visits) following the trial, and 80% participated in all three phases \[the treatment phase, the transition phase, and the post-trial follow-up phase (1--4 visits per year for 13 years)\]. Metabolomics and bronchodilator response data from participants (*N* = 295) from the post-trial follow-up phase were used in this analysis. The CAMP study was approved by the institutional review board of Partners Healthcare (Partners Human Research Committee; Protocol\#: 1999-P-001549/29), by all eight CAMP clinical centers, and by the CAMP Data Coordinating Center. Each child\'s parent or guardian signed a consent statement and the clinics obtained each child\'s assent.

Metabolomic profiling was performed on serum samples in CAMP (see [Supplementary Methods](#SM1){ref-type="supplementary-material"}). Features were analyzed as measured LC-MS peak areas, and log-transformed and *pareto* scaled prior to analysis. After QC and data processing a total of 501 named metabolites (see [Supplemental Table 1](#SM2){ref-type="supplementary-material"}) were identified by matching measured mass to charge ratio and retention time with authentic reference standards.

Lung function was measured by spirometry using a Survey Tach Spirometer (Warren E. Collins; Braintree, MA) in accordance with the American Thoracic Society recommendations. Prior to assessment, the children were told to withhold short-acting bronchodilators for at least 4 h. Spirometric maneuvers were conducted with the children seated and wearing a nose clip. The measurements were calibrated for gender, age and height according to reference values. After completing baseline spirometry, the children were given 200 μg (2 puffs) of an albuterol pressurized metered-dose inhaler (pMDI) using a spacer device. Spirometry was repeated after 15 min. BDR was defined as the best forced expiratory volume in the 1st second (FEV~1~) post-bronchodilator minus FEV~1~ pre-bronchodilator, divided by FEV~1~ pre-bronchodilator (expressed as a percentage).

For each individual metabolite mediator, we fit a linear regression model for bronchodilator response as the outcome and age as a predictor adjusting for the metabolite mediator and race, sex, treatment group and clinical site. We used a counterfactual framework for mediation analysis to estimate the indirect effects of age on BDR adjusting for race, sex, treatment group, and clinical site ([@B5], [@B6]). This method is implemented in the *medflex* package in *R* ([@B7]). We considered indirect effects at *p* \< 0.05 as potential metabolite mediators of age on BDR.

Results {#s3}
=======

Participant characteristics are shown in [Table 1](#T1){ref-type="table"}. Participants were 64% male, and the majority were of white race/ethnicity (72% white, 12% black, 7% Hispanic, and 9% other). Participants ranged in age from 12.2 to 25.9 years. The mean BDR was 8.0% and with a standard deviation of 7.0%. The top metabolite mediators were all phosphatidylcholine plasmalogens as shown in [Table 2](#T2){ref-type="table"}. Our results suggest that these metabolites may mediate the association of age with BDR (i.e., a portion of the reduction in BDR over time may be accounted for by age-related shifts in plasmalogen levels). These phosphatidylcholine plasmalogens were all highly correlated with one another (spearman *r* = 0.77--0.98).

###### 

Characteristics of CAMP participants with metabolomics data in the post-trial follow-up phase (total *N* = 295).

  **Characteristic**                             ***n***      **%**
  ------------------------ --------------------- ------------ ----------------
  Sex                      Male                  189          64.1%
                           Female                106          35.9%
  Race                     White                 213          72.2%
                           Black                 35           11.9%
                           Hispanic              21           7.1%
                           Other                 26           8.8%
  Treatment group          Budesonide            78           26.4%
                           Nedocromil            83           28.1%
                           Placebo               134          45.4%
  Age at blood sample      Mean (SD) \[range\]   16.8 (2.9)   \[12.2, 25.9\]
  \% BDR at blood sample   Mean (SD) \[range\]   8.0 (7.0)    \[−14, 49\]

###### 

Serum metabolite mediators for the association of age and bronchodilator response[^\*^](#TN1){ref-type="table-fn"}.

  **Metabolite**         **Average indirect effect of age through metabolite (beta)**   ***P*-value**
  ---------------------- -------------------------------------------------------------- ---------------
  C36:1 PC plasmalogen   −0.001                                                         0.006
  C36:3 PC plasmalogen   −0.002                                                         0.007
  C36:2 PC plasmalogen   −0.002                                                         0.01
  C36:4 PC plasmalogen   −0.001                                                         0.03

*Models adjusted for race, sex, clinical site, and treatment group*.

We also looked at correlation patterns within our metabolite data, and determined that phosphatidyl ethanolamine (PE) metabolites and sphingomyelin (SM) metabolites are correlated with circulating PC plasmalogens. \[Our main plasmalogen of interest (C36:1 PC plasmalogen), was correlated with PE metabolite levels (Spearman *r* = 0.71 for C38:2 PE, *r* = 0.74 for C36:2 PE plasmalogen) and with SM metabolites (Spearman *r* = 0.79 for C16:0 SM, *r* = 0.74 for C22:1 SM)\]. However, these PE and SM metabolites were not mediators of the association of age with bronchodilator response (*p* \> 0.6 for all indirect effects).

Conclusions {#s4}
===========

Plasmalogens are biologically plausible mediators of lung function responses, given their potential to alter the structural properties of lung surfactants ([@B8]). Plasmalogen levels are reduced following exposures known to exacerbate asthma (i.e., ozone) ([@B9]) and have been associated with a range of adverse respiratory health outcomes, including bronchopulmonary dysplasia in infants ([@B10]) and COPD in adults ([@B11]). Antioxidative effects of plasmalogens have been studied extensively both *in vitro* and *in vivo* ([@B12]), and may have relevance for bronchodilator response in asthma. Lastly, plasmalogens are biomarkers of the normal aging process ([@B13]), which further strengthens the evidence for these metabolites as age-related mediators of physiological responses.

Our study is the first to identify plasmalogens as possible mediators of age-related changes in lung function in individuals with asthma. Our findings suggest that plasmalogens may contribute to age-related asthma phenotypes, and may also serve as a potential pharmacologic target for enhancement of lung function in individuals with asthma.
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